Bed Bath & Beyond Added to Best Ideas List and Could Be Turning Around Soon
Bed Bath & Beyond stock has been beaten up so far this year, but one analyst thinks that it has the potential to rally.
All Work
Chris Lange
This Late-Stage Study Is Giving Satsuma Pharma Stock Migraines
After Satsuma Pharmaceuticals reported disappointing late-stage results from its migraine treatment, and its shares were absolutely crushed Thursday morning.
Innoviva Wins Another Key FDA Approval for Asthma
The FDA has approved Innoviva's treatment of asthma and for patients with chronic obstructive pulmonary disease, the company announced, giving shares a boost early Thursday.
5 Very Undervalued Large Cap Biotech Stocks That Could Explode in 2021
Practically any biotech company attempting almost anything COVID-19 related has seen massive gains. However, there is likely more to come for the rest of the year and into next year. These five stocks could…
Should Zscaler Get More Credit For Its Q4 Results?
Cloud computing company Zscaler released its fiscal fourth-quarter financial results after markets closed on Wednesday. The firm reported $0.05 in earnings per share (EPS) and $125.9 million in revenue, beating analysts' consensus estimate on…
GameStop Is Still In Trouble Despite Incredible E-Commerce Growth
GameStop posted a fiscal second-quarter net loss per share of $1.40 on $942.0 million in revenue. The consensus estimates had called for a net loss of $1.13 per share and $1.02 billion in revenue.
Academy Sports and Outdoors Plans to Come Public in Massive IPO
Sporting goods and outdoor recreational equipment retailer Academy Sports and Outdoors has filed for an initial public offering.
iBio Takes Another Big Step in the Fight Against COVID-19
iBio has announced that it has selected a vaccine to advance for the prevention of infection by the coronavirus that causes COVID-19.
Intra-Cellular Therapies Finds Euphoria in Bipolar Study Results
Intra-Cellular Therapies was one of the biggest winners on Wednesday after the company announced positive results from its late-stage clinical trial in patients with bipolar disorder.
StepStone Closes In on IPO With Potential Pricing
Investment firm StepStone intends to price more than 17 million shares to result in an initial public offering valued up to more than $342 million.
Why This FDA Update Is a Huge Step Forward for Precision BioSciences
A key update from the FDA on its treatment for relapsed/refractory multiple myeloma boosted Precision BioSciences shares early on Wednesday.
Slack Earnings Just Aren’t Enough For Investors
Slack reported fiscal second-quarter financial results after markets closed Tuesday showing breakeven earnings and $215.9 million in revenue, compared with consensus estimates for a net loss of $0.03 per share and $209.1 million in…
Lululemon Is Another Retailer Bucking the COVID-19 Trend
Lululemon released fiscal second-quarter results after markets closed Wednesday. The company reported $0.74 in earnings per share (EPS) and $902.9 million in revenue, compared with consensus estimates that called for $0.55 in EPS and…
Co-Diagnostics Roars Back With New COVID-19 Test Deal
Co-Diagnostics announced Tuesday that it has entered into an agreement with Arches Research to expand Arches' COVID-19 testing services using Co-Diagnostics’ test kit.
Why This Analyst Sees 25% More Upside in Apple
Many analysts have said that the market was running hot through August and now may be the time for it to cool off. Despite Tuesday’s pullback, one analyst sees Apple running much higher from…
Sumo Logic Announces Potential Pricing of IPO
Continuous intelligence pioneer Sumo Logic expects to price more than 14 million shares to result in an initial public offering valued up to more than $357 million.
Are More Positive Results on the Way for Kamada’s COVID-19 Pneumonia Treatment?
Kamada has announced initial interim results from its ongoing midstage coronavirus study of its treatment of COVID-19 patients with pneumonia.
Corbus Pharma Suffers Big Setback in Systemic Sclerosis Study
Corbus Pharmaceuticals has reported that its systemic sclerosis study failed to reach the endpoints, and investors were not pleased.
Does Broadcom Deserve More Credit For Q3?
After markets closed Thursday, Broadcom reported fiscal third-quarter earnings per share of $5.40 and revenue of $5.82 billion, compared with consensus estimates of $5.24 in EPS and revenue of $5.76 billion.
Safety Concern Offsets Chronic Kidney Disease Study Positive Results
On Thursday, Akebia Therapeutics Inc. (NASDAQ: AKBA) announced topline results from the Phase 3 PRO2TECT studies evaluating the safety and efficacy of vadadustat in chronic kidney disease (CKD). Shares were crushed afterward. This is…